Three more Vivus board members head for the door; Teva launches generic Lovaza in the U.S.;

@FiercePharma: Top-read FiercePharma news Tues.: Express Scripts assembling anti-Sovaldi coalition to shut out Gilead hep C drug. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. News | Follow @TracyStaton

@EricPFierce: FDA is beefing up its inspection staff in China but for now it has 2 drug inspectors in country. More | Follow @EricPFierce

@CarlyHFierce: From FiercePharmaMarketing: Facing a PR crisis? Teva France's chief has some hard-won advice. Article | Follow @CarlyHFierce

> Vivus ($VVUS) directors J. Martin Carroll, Robert Wilson and Mark Logan won't stand for reelection at the company's June 20 annual meeting. 8-K

> Mallinckrodt's ($MNK) $5.6 billion deal to buy Questcor Pharmaceuticals ($QCOR) pushed spending on specialty drugmaker deals in the past year to almost $60 billion, the most for a 12-month period since December 2009. Story

> Teva ($TEVA) has launced a U.S. generic of GlaxoSmithKline's ($GSK) fish oil pill Lovaza. Release

> The European Medicines Agency (EMA) will inspect Ranbaxy's Dewas, India, plant in June. More

Medical Device News

@FierceMedDev: Merck backs microbial Dx outfit as concern about treatment-resistant strains grows. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Deerfield unveils a $1.6B new fund as med tech VC lags. Story | Follow @VarunSaxena2

@EmilyWFierce: New book explores the evolutionary mystery of left-handedness. Article | Follow @EmilyWFierce

@MichaelGFierce: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. More from FierceDrugDelivery | Follow @MichaelGFierce

> InfoBionic brings in $17M to develop its cloud-based patient monitoring system. News

> Boston Scientific takes to Asia with its subcutaneous ICD. More

Biotech News

@FierceBiotech: Novartis, NEA join $188M gamble on China biotech fund. More | Follow @FierceBiotech

@JohnCFierce: After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky. Story | Follow @JohnCFierce

@DamianFierce: This AMA statement on the release of Medicare doctor payments is amazing, via Bloomberg News. Read | Follow @DamianFierce

@EmilyMFierce: In case you missed it here's this week's edition of FierceBiotech Research. Issue | Follow @EmilyMFierce

> 'Special K' once again wows investigators in small depression study. Story

> GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance. News

Drug Delivery News

> Nanoballoons 'pop' open to deliver cancer drugs when hit with a red laser. More

> Novaliq begins clinical trials for SFA-delivered cyclosporin eye drops. Story

> 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Article

> Magnetic nanoparticle hyperthermia with an antibody is effective in breast cancer cells. Report

> AACR: Gold nanorods aim cancer-killing lasers at the bladder. News

> AstraZeneca expands StarPharma deal for cancer drug delivery tech. Item

Diagnostics News

> Maryland Dx startup raises $2.8M to advance cancer genome analysis tech. Item

> Foundation Medicine will develop a test for Clovis' ovarian cancer drug. More

> Roche's Ventana pairs with Genmab on yet another companion Dx deal. Story

> Scripps scientists say new biomarker for various cancers might be more useful. Article

> Adaptive Biotechnologies grabs $105M from a single investor to boost its immune system test. Report

> Ysios is optimistic about diagnostic and device investments in 2014. Editor's corner

> Exact Sciences raises nearly $120M, focused on a hoped-for 2014 launch of its colon cancer Dx. News

> Merck led a $12M round for AdvanDx and its tests for tough hospital infections. More

Pharma Marketing News

> J&J sifts marketing nuggets from Mom's BabyCenter posts. Story

> Facing a PR crisis? Teva France's chief has some hard-won advice. More

> Patients are glued to iPhones and tablets, but pharma ads stick to TV. Article

> Which brands grab the drug-spending title? AbbVie's Humira, AZ's Nexium lead the way. News

> Bayer, J&J beef up Xarelto research to keep market-share gains coming. Report

> Teva puts GSK and Amarin on notice with generic Lovaza launch. Item

And Finally... Motivation to exercise--or lack thereof--may be at least partly inherited. Story (sub. req.)

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.